ライフサイエンスコーパス: endothelial marker

1 We previously identified CLEC14A as a tumour endothelial marker.

2 er have focal regions that lack these common endothelial markers.

3 technology is useful for in vivo imaging of endothelial markers.

4 ally new pan-endothelial and tissue-specific endothelial markers.

5 5+ and are thought to lose the expression of endothelial markers.

6 sing human specific hepatocyte, biliary, and endothelial markers.

7 lial dysfunction, as assessed by circulating endothelial markers.

8 of all dividing cells are immunoreactive for endothelial markers.

9 ting in formation of blood and activation of endothelial markers.

10 h native endothelium and express all studied endothelial markers.

11 the cells coexpressed arterial and lymphatic endothelial markers.

12 and retained expression of general vascular endothelial markers.

13 and graft outcomes to a greater extent than endothelial markers.

14 zed by immunoreactivity for cytokeratins and endothelial markers.

15 fferentiation and sustains the expression of endothelial markers.

16 ALK2, chondrocytes and osteoblasts expressed endothelial markers.

17 SECs have both hematopoietic and endothelial markers.

18 scular endothelial growth factor (VEGF), and endothelial markers.

19 in a two-step screen to predict novel tumour endothelial markers.

20 e subtraction was employed to predict tumour endothelial markers.

21 nesium intake is related to inflammatory and endothelial markers.

22 tric analysis and quantifying mRNA levels of endothelial markers.

23 and showed varying immunoreactivity for all endothelial markers.

24 Tumor endothelial marker 1 (TEM1/endosialin) is a tumor vascul

25 Tumor endothelial marker 1 (TEM1; also known as endosialin or

26 Tumor endothelial marker 1 (Tem1; endosialin) is the prototypi

27 Human tumor endothelial marker 1/endosialin (TEM1/endosialin) was re

28 CD248 (tumor endothelial marker 1/endosialin) is found on stromal cel

29 (alternatively known as endosialin or tumour endothelial marker-1) is also a member of this family an

30 rated by immunostaining for with a lymphatic endothelial marker 10.1.1.

31 One binding partner was identified as tumor endothelial marker-4 (TEM4; ARHGEF17), a guanine nucleot

32 protein-coupled receptor (GPCR) GPR124/tumor endothelial marker 5 is highly expressed in central nerv

33 protein-coupled receptor 124 (GPR124) (tumor endothelial marker 5, TEM5), an orphan member of the adh

34 Tumor endothelial marker 7 (TEM7) was recently identified as a

35 in 2 (CMG2) and anthrax toxin receptor/tumor endothelial marker 8 (ATR/TEM8).

36 eceptors, anthrax toxin receptor (ATR)/tumor endothelial marker 8 (TEM8) and capillary morphogenesis

37 wo identified anthrax toxin receptors: tumor endothelial marker 8 (TEM8) and capillary morphogenesis

38 toxin receptors (ATRs), encoded by the tumor endothelial marker 8 (TEM8) gene.

39 Tumor endothelial marker 8 (TEM8) is a recently described prot

40 Tumor endothelial marker 8 (TEM8) is induced in tumor-associat

41 Anthrax toxin receptor 1 (ANTXR1)/tumor endothelial marker 8 (TEM8) is one of two known proteina

42 sured in cells specifically expressing tumor endothelial marker 8 (TEM8) or capillary morphogenesis p

43 ins, protective antigen (PA), binds to tumor endothelial marker 8 (TEM8) or capillary morphogenesis p

44 he more important for pathogenesis and tumor endothelial marker 8 (TEM8) playing a minor role.

45 Tumor endothelial marker 8 (TEM8) was initially identified as

46 Tumor endothelial marker 8 (TEM8), also known as anthrax toxin

47 Surface expression of toxin receptors tumor endothelial marker 8 and capillary morphogenesis gene 2,

48 The soluble anthrax toxin receptor/tumor endothelial marker 8 and capillary morphogenesis protein

49 ular receptors: anthrax toxin receptor/tumor endothelial marker 8 and capillary morphogenesis protein

50 The anthrax toxin receptor/tumor endothelial marker 8 and CMG2 VWA domains share approxim

51 llary morphogenesis gene 2 protein and tumor endothelial marker 8 with high affinity.

52 capillary morphogenesis gene 2 (CMG2), tumor endothelial marker 8, and beta1-integrin, and, with the

53 ary morphogenesis protein-2 (CMG-2) or tumor endothelial marker-8 (TEM-8), which triggers the binding

54 1 integrin, the integrin-like receptor tumor endothelial marker-8 (TEM8), VEGFR2 and NFAT.

55 We therefore measured a panel of plasma endothelial markers acutely and in convalescence in Mala

56 e differentiated cells co-expressed CD31, an endothelial marker, along with alpha-SMA, as seen by dou

57 Glut1 is an endothelial marker and is the principal glucose transpor

58 ascular endothelial cells lost expression of endothelial markers and acquired expression of mesenchym

59 "Transitional" cells, coexpressing both endothelial markers and alpha-SM-actin, were consistentl

60 Similarly, this co-expression of endothelial markers and alpha-SMA was detected in a subp

61 e change in the EYFP population with loss of endothelial markers and an increase in mononuclear marke

62 of circulation express the highest levels of endothelial markers and do not generate blood cells in v

63 -1 and podoplanin used as specific lymphatic endothelial markers and Ki-67 as a proliferation marker.

64 tures that were positive for three lymphatic endothelial markers and negative for three blood vessel

65 ead showed the stable expression of multiple endothelial markers and the capacity to form capillary n

66 the absence of RUNX1, the down-regulation of endothelial markers and the formation of round cells, a

67 ulting models, the expression of cardiac and endothelial markers and the perfusion of the system was

68 identification of tissue-specific lymphatic endothelial markers and the study of congenital lymphede

69 Combining these 2 functional endothelial markers and using confocal microscopy to obt

70 s based on the expression of VE-cadherin and endothelial markers and with lack of CD45 and hematopoie

71 neuronal marker; vWF, VEGFA, VEGFC and IL-8, endothelial markers; and PPARgamma and FABP4, adipose ma

72 n of transductional targeting to a pulmonary endothelial marker (angiotensin-converting enzyme, ACE)

73 YFP reporter quail embryos combined with the endothelial marker antibody QH1 provides definitive evid

74 These cells express endothelial markers, are heterogeneous for early hematop

75 ated into ECs (miPSC-ECs), the expression of endothelial markers, arterial endothelial markers, pro-a

76 nments recruit progenitor cells that express endothelial markers, as determined by staining with isol

77 f cDNA libraries and predict putative tumour endothelial markers before entering the laboratory.

78 The clones expressed endothelial markers but showed potential to further diff

79 Acquisition of endothelial markers by activated T cells occurred as par

80 phatics display a typical panel of lymphatic endothelial markers by immunohistochemistry.

81 bed the heart vasculature for heart-specific endothelial markers by phage display.

82 ely 30 to 50% of fibroblasts coexpressed the endothelial marker CD31 and markers of fibroblasts and m

83 report, the co-expression of HLA-DR and the endothelial marker CD31 are used to identify RMEC as a d

84 lonal lines showed reduced staining with the endothelial marker CD31 in Matrigel plug assay, indicati

85 1 was specifically colocalized with vascular endothelial marker CD31 surrounded by type IV collagen.

86 tained with Cy-annexin V and antibody to the endothelial marker CD31).

87 C1 expression closely paralleled that of the endothelial marker CD31, and the peak level of STC1 expr

88 stem cell marker SCA-1, also co-express the endothelial marker CD31, suggesting the presence of endo

89 in level of staining for TGF-betaRII or the endothelial marker CD31.

90 ith the podocyte marker WT1 but not with the endothelial marker CD31.

91 lpha(1), alpha(2), beta(3), and beta(5); the endothelial marker CD31; and metalloproteinases MMP-2 an

92 wth and immunohistochemical staining for the endothelial markers CD31 and VEGFR-2 and terminal deoxyn

93 (GATA4, HAND1, MEF2C, NKX2.5, and TBX5) and endothelial markers (CD31, FLK1, FLT1, VWF).

94 on-induced angiogenesis and a panel of known endothelial markers (CD31, VE-cadherin, BS-I lectin), we

95 negative for: hematopoietic (CD34, CD45) and endothelial markers (CD31, vWf, von Willebrand factor).

96 ith colocalization studies with TUNEL and an endothelial marker, CD31, in tumor sections of Ad-MMP-2-

97 hemically characterized by the expression of endothelial markers, CD31, and P1H12.

98 ained prostatectomy tumor block sections for endothelial marker CD34 and assessed microvessel density

99 d the expression of HIF1alpha, VEGF, and the endothelial marker CD34 in a mouse xenograft model of br

100 significant correlation between SUV(max) and endothelial markers (CD34 and CD105).

101 l growth factor receptor 3) as well as blood endothelial markers (CD34, endomucin, platelet endotheli

102 Endothelial markers colocalize with multipotent and oste

103 sed and presented differential expression of endothelial markers compared to WT.

104 hogenesis of PPH; the normalization of these endothelial markers concomitant with improvement in hemo

105 on of proangiogenic markers, the increase in endothelial markers does not correlate with the dysregul

106 or inhibitor-1, protein C, antithrombin, and endothelial markers (E-selectin, intracellular adhesion

107 ur study demonstrates a critical role of the endothelial marker EMCN in supporting normal glomerular

108 induced endothelium dysfunction, we measured endothelial markers, endothelium-dependent vasodilation,

109 injury models may induce lineage-independent endothelial marker expression in mesenchymal cells.

110 with formation of microtubules and increased endothelial marker expression in the cavernosa.

111 The SMC-converted ECs exhibit typical endothelial markers expression and endothelial functions

112 However, the expression of an early endothelial marker fli1a and vascular morphogenesis appe

113 uently differentiate into cells that express endothelial markers, function in vitro as mature endothe

114 d consistent up-regulation of certain glioma endothelial marker genes across patient samples.

115 erocytes, are present in mice and identified endothelial marker genes conserved in humans and mice.

116 We observed a reduction in endothelial marker genes PECAM1, VWF and CDH5 in GDM pla

117 A decrease is observed in endothelial marker genes.

118 ith antiserum to human ecNOS, the functional endothelial marker GLUT1, and the anatomical endothelial

119 Inclusion of the endothelial markers ICAM1 and thrombomodulin in a logist

120 lly using podoplanin as a specific lymphatic endothelial marker in 21 globes that had been enucleated

121 diac function by improving the expression of endothelial markers in MEndoT-derived cells.

122 27 genes were predicted tumour endothelial markers in multiple tissues based on the sec

123 th muscle actin, but negative for desmin and endothelial markers including Factor VIII, clonal design

124 , designated IEM, which expresses a range of endothelial markers, including Von Willibrand Factor VII

125 We have shown that podoplanin, a lymphatic endothelial marker, is highly expressed in oral cancer a

126 t ARHGEF17, originally identified as a tumor endothelial marker, is involved in tumor growth and meta

127 Correlations between endothelial marker levels and shock severity were assess

128 adventitia and lacked surface expression of endothelial markers (<1% for CD31, CD144, TIE-2).

129 double immunostains for the novel lymphatic endothelial marker LYVE-1 and for the panvascular marker

130 munohistochemical staining for the lymphatic endothelial marker LYVE-1 was done to determine the cont

131 sed expression pattern and co-localised with endothelial markers on sinusoidal endothelium.

132 , more than 86% of these cells expressed the endothelial markers P1H12, CD34, and CD31 and leukocyte

133 smooth muscle (SM) alpha-actin; whereas the endothelial marker, PECAM-1, was lost from the invaded c

134 Despite a reduction in endothelial markers, PECAM1, VWF and CDH5, as well as SN

135 bryos based on the lack of expression of the endothelial marker platelet endothelial cell adhesion mo

136 nto immunoliposomes (Ab-MJ33/IL) targeted to endothelial marker platelet endothelial cell adhesion mo

137 a cobblestone cell morphology, expression of endothelial markers (platelet endothelial cell-adhesion

138 EM and immunohistochemical staining with the endothelial marker, platelet and endothelial cell adhesi

139 Immunostaining of an endothelial marker, platelet endothelial cell adhesion m

140 1), a mediator of vasoconstriction; CD31, an endothelial marker; platelet-derived growth factor-beta

141 receptor (LYVE-1, a routinely used lymphatic endothelial marker), podoplanin, Flt4/VEGFR3, Sca-1, CD1

142 g/ml each), explants formed QH-1 (anti-quail endothelial marker)-positive mesenchymal cells, which in

143 -Bromo-2'-deoxyuridine incorporation and neo-endothelial markers present in the microvasculature of M

144 expression of endothelial markers, arterial endothelial markers, pro-angiogenic cytokines, and Notch

145 schaemic leukoaraiosis group had a different endothelial marker profile, with lower levels of TFPI (P

146 These tumor endothelial marker proteins also exhibited increased exp

147 Access to highly specific tumor endothelial markers provides opportunities for direct ta

148 Based on the expression of an quail endothelial marker, QH-1, the initial emergence of endot

149 cular endothelial-cadherin, and CD34) and an endothelial marker recognized by Griffonia simplicifolia

150 and Ephrin receptor B4, arterial and venous endothelial markers, respectively.

151 d to tissues undergoing inflammation, and an endothelial marker responsible for tumour homing to the

152 entified by expression of lacZ and Flt-1, an endothelial marker shown to be absent on SP cells.

153 e the liver sinusoids and express sinusoidal endothelial markers similar to those in normal liver tis

154 rived CD11b+ macrophages expressed lymphatic endothelial markers such as LYVE-1 and Prox-1 under infl

155 were characterized with highly expression of endothelial markers such as vascular endothelial cadheri

156 pulations uniformly co-expressed myeloid and endothelial markers, suggesting that peripheral blood pr

157 totrophoblasts fail to express most of these endothelial markers, suggesting that this adhesion pheno

158 pha1, Ialpha2, and IIIalpha1 are known tumor endothelial markers, suggesting that TSP1 coordinately r

159 Tumor endothelial marker (TEM)8 was uncovered as a gene expres

160 Tumor endothelial markers (TEM) are antigens enriched in tumor

161 Tumor endothelial markers (TEMs) that are highly expressed in

162 We recently identified genes encoding tumor endothelial markers (TEMs) that displayed elevated expre

163 d through the recent identification of tumor endothelial markers (TEMs).

164 Aggressive melanoma cells may express endothelial markers that can be used to calculate microv

165 As CD34(+) cells acquired mature endothelial markers, they exhibit robust oscillations of

166 d xenografts (PDXs) were found to co-express endothelial marker Tie-2.

167 Based on protein expression levels of common endothelial markers using flow cytometry, 3 subpopulatio

168 Cells expressing the lymphatic endothelial marker vascular endothelial growth factor re

169 r percentage of cells expressed the specific endothelial marker VE-cadherin (5.2+/-0.7%) or stem/prog

170 growth, but some leukocytes up-regulated the endothelial marker VE-cadherin.

171 f mesenchymal markers and down-regulation of endothelial markers via transforming growth factor/Smad

172 endothelial marker GLUT1, and the anatomical endothelial marker von Willebrand factor.

173 , left ventricular protein expression of the endothelial markers von Willebrand factor and neuregulin

174 reproducible, and show characteristic brain endothelial markers (von Willebrand factor, glucose tran

175 ; in both places, it is co-localized with an endothelial marker, von Willebrand factor, and laminin-1

176 xpression occurred together with that of the endothelial marker, von Willebrand factor, in human and

177 Immunostaining of the endothelial marker vWf revealed a parallel upregulation

178 for identification of highly selective tumor endothelial markers was conducted to develop targeted an

179 The greatest immunoreactivity for endothelial markers was observed with CD34 and vWF and l

180 ionally, K(ATP) channel co-localization with endothelial markers was reduced in the high-altitude myo

181 A new leukocyte population expressing DC and endothelial markers was uncovered in mouse and human ova

182 To identify tumor-specific endothelial markers, we performed a microarray on tumor-

183 that localized to the lumen and stained for endothelial markers were also identified.

184 cells coexpressing cytokeratins and the two endothelial markers were clearly identifiable.

185 Most of these tumor endothelial markers were expressed in a wide range of tu

186 Endothelial markers were more often significantly associ

187 Endothelial markers were not consistently associated wit

188 Endothelial markers were positive only in the single lay

189 In contrast, endothelial markers were similar to lower at Day 0 for i

190 pha, or IL-1beta decreased the expression of endothelial markers, whereas mesenchymal markers increas

191 the first step towards identifying selective endothelial markers, which may be useful in targeting ce

192 e G-protein-coupled receptor RDC1 as a tumor endothelial marker whose expression is distinctly induce

193 actin (a marker of arterioles) and CD34 (an endothelial marker), with separate analyses on grey and

194 in the lungs, specifically associating with endothelial markers, without apparent histological chang